INDV
Indivior Pharmaceuticals Inc
Drug Manufacturers - Specialty & Generic
Market Cap$4.94B
5Y Perf.+164.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
INDV vs BHVN
Revenue, margins, valuation, and 5-year total return — side by side.
BHVN
Biohaven Ltd.
Biotechnology
Market Cap$1.03B
5Y Perf.+54.5%
INDV vs BHVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | INDV | BHVN |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $4.94B | $1.03B |
| Revenue (TTM) | $1.29B | $0.00 |
| Net Income (TTM) | $251M | $-648M |
| Gross Margin | 83.1% | — |
| Operating Margin | 33.3% | — |
| Forward P/E | 12.7x | — |
| Total Debt | $351M | $279M |
| Cash & Equiv. | $195M | $230M |
INDV vs BHVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
INDV
BHVN
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| Indivior Pharmaceut… (INDV) | 100 | 264.0 | +164.0% |
| Biohaven Ltd. (BHVN) | 100 | 154.5 | +54.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INDV vs BHVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INDV leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Biohaven Ltd. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
INDV
Indivior Pharmaceuticals Inc
The Income Pick
INDV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.68
- Rev growth 4.3%, EPS growth 108.3%, 3Y rev CAGR 11.2%
- 281.7% 10Y total return vs BHVN's 33.4%
Best for: income & stability and growth exposure
BHVN
Biohaven Ltd.
The Growth Leader
BHVN is the clearest fit if your priority is growth.
- 27.3% revenue growth vs INDV's 4.3%
Best for: growth
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BHVN | 27.3% revenue growth vs INDV's 4.3% |
| Quality / Margins | INDV | 19.4% margin vs BHVN's 3.2% |
| Stability / Safety | INDV | Beta 0.68 vs BHVN's 1.35 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | INDV | +244.9% vs BHVN's -48.8% |
| Efficiency (ROA) | INDV | 19.1% ROA vs BHVN's -138.0%, ROIC 342.7% vs -242.1% |
INDV vs BHVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
INDV vs BHVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINDVLAGGINGBHVN
BHVNBiohaven Ltd.
1leads
INDVIndivior Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs BHVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INDV1/1
Valuation MetricsMultiples, price ratios, and targets
BHVN1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INDV4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
INDV6/6
Risk & VolatilityBeta, volatility, and downside exposure
INDV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
INDV leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
INDV and BHVN operate at a comparable scale, with $1.3B and $0 in trailing revenue.
| Metric | INDVIndivior Pharmace… | BHVNBiohaven Ltd. |
|---|---|---|
| RevenueTrailing 12 months | $1.3B | $0 |
| EBITDAEarnings before interest/tax | $447M | -$646M |
| Net IncomeAfter-tax profit | $251M | -$648M |
| Free Cash FlowCash after capex | -$185M | -$594M |
| Gross MarginGross profit ÷ Revenue | +83.1% | — |
| Operating MarginEBIT ÷ Revenue | +33.3% | — |
| Net MarginNet income ÷ Revenue | +19.4% | — |
| FCF MarginFCF ÷ Revenue | -14.3% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +19.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +81.6% | +59.4% |
INDV leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BHVN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | INDVIndivior Pharmace… | BHVNBiohaven Ltd. |
|---|---|---|
| Market CapShares × price | $4.9B | $1.0B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $1.1B |
| Trailing P/EPrice ÷ TTM EPS | 24.15x | -1.42x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.65x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.88x | — |
| Price / SalesMarket cap ÷ Revenue | 3.99x | — |
| Price / BookPrice ÷ Book value/share | — | 20.12x |
| Price / FCFMarket cap ÷ FCF | — | — |
BHVN leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
INDV leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), INDV scores 4/9 vs BHVN's 2/9, reflecting mixed financial health.
| Metric | INDVIndivior Pharmace… | BHVNBiohaven Ltd. |
|---|---|---|
| ROE (TTM)Return on equity | — | -8.7% |
| ROA (TTM)Return on assets | +19.1% | -138.0% |
| ROICReturn on invested capital | +3.4% | -2.4% |
| ROCEReturn on capital employed | +79.1% | -187.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 5.36x |
| Net DebtTotal debt minus cash | $156M | $49M |
| Cash & Equiv.Liquid assets | $195M | $230M |
| Total DebtShort + long-term debt | $351M | $279M |
| Interest CoverageEBIT ÷ Interest expense | 10.88x | — |
INDV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
INDV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INDV five years ago would be worth $36,837 today (with dividends reinvested), compared to $13,336 for BHVN. Over the past 12 months, INDV leads with a +244.9% total return vs BHVN's -48.8%. The 3-year compound annual growth rate (CAGR) favors INDV at 25.4% vs BHVN's -11.8% — a key indicator of consistent wealth creation.
| Metric | INDVIndivior Pharmace… | BHVNBiohaven Ltd. |
|---|---|---|
| YTD ReturnYear-to-date | +10.8% | -10.2% |
| 1-Year ReturnPast 12 months | +244.9% | -48.8% |
| 3-Year ReturnCumulative with dividends | +97.0% | -31.5% |
| 5-Year ReturnCumulative with dividends | +268.4% | +33.4% |
| 10-Year ReturnCumulative with dividends | +281.7% | +33.4% |
| CAGR (3Y)Annualised 3-year return | +25.4% | -11.8% |
INDV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
INDV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
INDV is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than BHVN's 1.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INDV currently trades 96.6% from its 52-week high vs BHVN's 44.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INDVIndivior Pharmace… | BHVNBiohaven Ltd. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.68x | 1.35x |
| 52-Week HighHighest price in past year | $41.00 | $22.05 |
| 52-Week LowLowest price in past year | $10.63 | $7.48 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +44.1% |
| RSI (14)Momentum oscillator 0–100 | 79.6 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 2.6M | 2.0M |
INDV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates INDV as "Buy" and BHVN as "Buy". Consensus price targets imply 118.7% upside for BHVN (target: $21) vs 12.8% for INDV (target: $45).
| Metric | INDVIndivior Pharmace… | BHVNBiohaven Ltd. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $44.67 | $21.29 |
| # AnalystsCovering analysts | 3 | 25 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
INDV leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BHVN leads in 1 (Valuation Metrics).
Best OverallIndivior Pharmaceuticals Inc (INDV)Leads 4 of 6 categories
Loading custom metrics...
INDV vs BHVN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is INDV or BHVN a better buy right now?
Indivior Pharmaceuticals Inc (INDV) offers the better valuation at 24.
1x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate Indivior Pharmaceuticals Inc (INDV) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INDV or BHVN?
Over the past 5 years, Indivior Pharmaceuticals Inc (INDV) delivered a total return of +268.
4%, compared to +33. 4% for Biohaven Ltd. (BHVN). Over 10 years, the gap is even starker: INDV returned +281. 7% versus BHVN's +33. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INDV or BHVN?
By beta (market sensitivity over 5 years), Indivior Pharmaceuticals Inc (INDV) is the lower-risk stock at 0.
68β versus Biohaven Ltd. 's 1. 35β — meaning BHVN is approximately 99% more volatile than INDV relative to the S&P 500.
04Which is growing faster — INDV or BHVN?
On earnings-per-share growth, the picture is similar: Indivior Pharmaceuticals Inc grew EPS 108.
3% year-over-year, compared to 26. 1% for Biohaven Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — INDV or BHVN?
Indivior Pharmaceuticals Inc (INDV) is the more profitable company, earning 16.
9% net margin versus 0. 0% for Biohaven Ltd. — meaning it keeps 16. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INDV leads at 21. 4% versus 0. 0% for BHVN. At the gross margin level — before operating expenses — INDV leads at 80. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is INDV or BHVN more undervalued right now?
Analyst consensus price targets imply the most upside for BHVN: 118.
7% to $21. 29.
07Which pays a better dividend — INDV or BHVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is INDV or BHVN better for a retirement portfolio?
For long-horizon retirement investors, Indivior Pharmaceuticals Inc (INDV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
68), +281. 7% 10Y return). Both have compounded well over 10 years (INDV: +281. 7%, BHVN: +33. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between INDV and BHVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.